Toxicity-Driven Dose Adaptation of ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Clinical Practice: A Single-Center Experience (EANM 2026) - Sep 29, 2026 - Abstract #EP-0919; P2 | "LuPSMA demonstrated a well-defined safety profile. In our cohort, a small subset of patients required dose reduction due to relevant toxicities. Although limited by the small sample size, these findings suggest that individualized dose adaptation may be a valuable strategy in selected frail patients to maintain treatment feasibility without compromising overall therapeutic intent."
Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Renal Disease • Solid Tumor • Thrombocytopenia
|
|
I. Marini 1; M. Sansovini 1; S. Nicolini 1; M. Celli 1; E. F. Giunta 2; G. Schepisi 2; F. Foca 3; A. Sarnelli 4; V. Di Iorio 5; L. Vizza 3; E. Giani 3; M. Monti 3; P. Caroli 1; F. Matteucci 1; I. Grassi 1
|